Colombia sets Kaletra price ceiling
This article was originally published in Scrip
The Colombian government has set a maximum price for Abbott's Kaletra (lopinavir plus ritonavir), reducing the private sector price by around 55%. However, civil society is still pushing for the government to issue a compulsory licence.
You may also be interested in...
Draft guidelines due out for consultation this week in Italy are expected to shed more light on what companies will have to reveal during pricing and reimbursement negotiations.
Germany is for the first time to adopt national guidelines on prescribing biologics and biosimilars in a move towards increasing biosimilar uptake.
EFPIA, the European Federation of Pharmaceutical Industries and Associations, has put forward what it thinks the European regulatory network strategy to 2025 should prioritize.